

Lorenzo Dagna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5950339/publications.pdf>

Version: 2024-02-01

290
papers

11,531
citations

36303

51
h-index

39675

94
g-index

299
all docs

299
docs citations

299
times ranked

15457
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e325-e331.	3.9	808
2	Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 319-329.	22.7	594
3	Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 483-492.	1.4	462
4	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1752-1760.	30.7	353
5	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. <i>European Journal of Internal Medicine</i> , 2020, 76, 43-49.	2.2	349
6	Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2020, 22, 95-97.	0.1	253
7	Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. <i>Clinical Microbiology and Infection</i> , 2021, 27, 451-457.	6.0	243
8	Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. <i>Clinical Immunology</i> , 2020, 217, 108509.	3.2	236
9	Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2020, 22, 95-97.	0.1	235
10	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1277-1285.	0.9	212
11	Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 522-532.	10.7	195
12	Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. <i>Blood</i> , 2020, 135, 1929-1945.	1.4	191
13	Eosinophils from Physiology to Disease: A Comprehensive Review. <i>BioMed Research International</i> , 2018, 2018, 1-28.	1.9	182
14	GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e465-e473.	3.9	173
15	The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1691-1695.	0.9	163
16	Ventricular Arrhythmias in Myocarditis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1046-1057.	2.8	148
17	Human $\gamma\delta$ T cells: a nonredundant system in the immune-surveillance against cancer. <i>Trends in Immunology</i> , 2002, 23, 14-18.	6.8	144
18	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e253-e261.	3.9	140

#	ARTICLE	IF	CITATIONS
19	Pentraxin-3 as a Marker of Disease Activity in Takayasu Arteritis. <i>Annals of Internal Medicine</i> , 2011, 155, 425.	3.9	129
20	Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2020, 22, 200-211.	0.1	128
21	Erdheim-Chester disease. <i>European Journal of Internal Medicine</i> , 2015, 26, 223-229.	2.2	123
22	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology</i> , The, 2021, 3, e690-e697.	3.9	121
23	Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. <i>Arthritis and Rheumatism</i> , 2010, 62, 2530-2535.	6.7	109
24	Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 1625.	4.8	108
25	IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 135-145.	1.1	106
26	Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International) Trial. <i>Arthritis and Rheumatism</i> , 2017, 59, 956-964.	1.8	98
27	Selective suppression of IL-12 production by human herpesvirus 6. <i>Blood</i> , 2003, 102, 2877-2884.	1.4	94
28	BRAF ^{V600E} -mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1596-1602.	0.9	94
29	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 369.	3.5	89
30	MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1363-1368.	7.1	88
31	Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2313-2318.	7.1	87
32	A CD8 ^{hi} Subset of CD4 ⁺ SLAMF7 ⁺ Cytotoxic T Cells Is Expanded in Patients With IgG4-Related Disease and Decreases Following Glucocorticoid Treatment. <i>Arthritis and Rheumatology</i> , 2018, 70, 1133-1143.	5.6	87
33	Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2020, 22, 91-94.	0.1	87
34	IL-18 and infections: Is there a role for targeted therapies?. <i>Journal of Cellular Physiology</i> , 2021, 236, 1638-1657.	4.1	83
35	Tumor Necrosis Factor α As a Master Regulator of Inflammation in Erdheim-Chester Disease: Rationale for the Treatment of Patients With Infliximab. <i>Journal of Clinical Oncology</i> , 2012, 30, e286-e290.	1.6	79
36	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	5.6	78

#	ARTICLE	IF	CITATIONS
37	Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. <i>Rheumatology</i> , 2016, 55, 2220-2229.	1.9	77
38	Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 48-54.	3.4	75
39	Treating Life-Threatening Myocarditis by Blocking Interleukin-1*. <i>Critical Care Medicine</i> , 2016, 44, e751-e754.	0.9	75
40	Candidemia in Coronavirus Disease 2019 (COVID-19) Patients: Incidence and Characteristics in a Prospective Cohort Compared With Historical Non-“COVID-19 Controls. <i>Clinical Infectious Diseases</i> , 2021, 73, e2838-e2839.	5.8	72
41	The Relapsing Polychondritis Disease Activity Index: Development of a disease activity score for relapsing polychondritis. <i>Autoimmunity Reviews</i> , 2012, 12, 204-209.	5.8	71
42	Treating COVID-19 with colchicine in community healthcare setting. <i>Clinical Immunology</i> , 2020, 217, 108490.	3.2	69
43	Predictors of Pneumothorax/Pneumomediastinum in Mechanically Ventilated COVID-19 Patients. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 3642-3651.	1.3	67
44	Efficacy and safety of biological agents in adult-onset Still’s disease. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 309-314.	1.1	66
45	Inherited Perforin and Fas Mutations in a Patient with Autoimmune Lymphoproliferative Syndrome and Lymphoma. <i>New England Journal of Medicine</i> , 2004, 351, 1419-1424.	27.0	65
46	Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.. <i>European Journal of Internal Medicine</i> , 2021, 86, 34-40.	2.2	61
47	Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. <i>Rheumatology</i> , 2017, 56, 2084-2092.	1.9	60
48	Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2020, , .	0.1	59
49	Takayasu Arteritis: Intravascular Contrast Medium for MR Angiography in the Evaluation of Disease Activity. <i>American Journal of Roentgenology</i> , 2012, 198, W279-W284.	2.2	58
50	Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 498-503.	5.6	55
51	Methotrexate for maintenance of remission in IgG4-related disease: Fig. 1. <i>Rheumatology</i> , 2015, 54, 1934-1936.	1.9	54
52	Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure. <i>Frontiers in Immunology</i> , 2017, 8, 131.	4.8	53
53	Myocarditis: An Interleukin-1-Mediated Disease?. <i>Frontiers in Immunology</i> , 2018, 9, 1335.	4.8	53
54	Prevalence, Characteristics, Risk Factors, and Outcomes of Invasively Ventilated COVID-19 Patients with Acute Kidney Injury and Renal Replacement Therapy. <i>Blood Purification</i> , 2021, 50, 102-109.	1.8	53

#	ARTICLE	IF	CITATIONS
55	Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease. <i>European Journal of Internal Medicine</i> , 2020, 74, 92-98.	2.2	52
56	COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1150-1157.	3.4	52
57	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 724-726.	0.9	51
58	Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1252-1253.	0.9	51
59	Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. <i>Rheumatology</i> , 2010, 49, 1203-1206.	1.9	49
60	Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. <i>Microvascular Research</i> , 2021, 133, 104071.	2.5	49
61	Efficacy and safety of mavrimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 653-661.	0.9	49
62	Treating Pulmonary Silicosis by Blocking Interleukin 1. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 596-598.	5.6	48
63	Immunomodulation and immunosuppression by human herpesvirus 6A and 6B. <i>Future Virology</i> , 2013, 8, 273-287.	1.8	46
64	Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. <i>Rheumatology</i> , 2020, 59, 2435-2442.	1.9	46
65	Pulmonary Vascular Thrombosis in COVID-19 Pneumonia. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 3631-3641.	1.3	46
66	Giant cell arteritis restricted to the limb arteries: An overlooked clinical entity. <i>Autoimmunity Reviews</i> , 2015, 14, 352-357.	5.8	44
67	Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 536-544.	0.9	44
68	Assessment of Takayasu Arteritis Activity by Carotid Contrast-Enhanced Ultrasound. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, e1-2.	2.6	43
69	Low prevalence of arrhythmias in clinically stable COVID-19 patients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 891-893.	1.2	43
70	Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse. <i>Arthritis Research and Therapy</i> , 2018, 20, 222.	3.5	41
71	Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. <i>European Journal of Internal Medicine</i> , 2021, 93, 87-94.	2.2	41
72	Oncogene-Induced Senescence as a New Mechanism of Disease: The Paradigm of Erdheim-Chester Disease. <i>Frontiers in Immunology</i> , 2014, 5, 281.	4.8	40

#	ARTICLE	IF	CITATIONS
73	The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity. <i>Cell Reports</i> , 2021, 35, 108955.	6.4	40
74	Inflammation as a Predictor of Recurrent Ventricular Tachycardia After Ablation in Patients With Myocarditis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1644-1656.	2.8	39
75	The right place for IL-1 inhibition in COVID-19. <i>Lancet Respiratory Medicine</i> , 2021, 9, 223-224.	10.7	39
76	Two-months quality of life of COVID-19 invasively ventilated survivors; an Italian single-center study. <i>Acta Anaesthesiologica Scandinavica</i> , 2021, 65, 912-920.	1.6	39
77	Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 1-3.	4.1	38
78	Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease. <i>Frontiers in Immunology</i> , 2018, 9, 1233.	4.8	37
79	Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. <i>European Journal of Internal Medicine</i> , 2018, 57, e11-e12.	2.2	36
80	Biobanking for COVID-19 research. <i>Panminerva Medica</i> , 2022, 64, .	0.8	36
81	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019, 10, 296.	3.5	35
82	Stranger Months: How SARS-CoV-2, Fear of Contagion, and Lockdown Measures Impacted Attendance and Clinical Activity During February and March 2020 at an Urban Emergency Department in Milan. <i>Disaster Medicine and Public Health Preparedness</i> , 2021, 15, e33-e42.	1.3	35
83	Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 675678.	4.8	35
84	Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. <i>Rheumatology</i> , 2020, 59, 2523-2533.	1.9	35
85	Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. <i>Annals of Internal Medicine</i> , 2018, 169, 819.	3.9	34
86	Impact of systemic immune-mediated diseases on clinical features and prognosis of patients with biopsy-proved myocarditis. <i>International Journal of Cardiology</i> , 2019, 280, 110-116.	1.7	33
87	One-Year Multidisciplinary Follow-Up of Patients With COVID-19 Requiring Invasive Mechanical Ventilation. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 1354-1363.	1.3	33
88	Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1221-1234.	3.2	32
89	Obesity and its role in the management of rheumatoid and psoriatic arthritis. <i>Clinical Rheumatology</i> , 2020, 39, 1039-1047.	2.2	32
90	Pneumothorax/pneumomediastinum in non-intubated COVID-19 patients: Differences between first and second Italian pandemic wave. <i>European Journal of Internal Medicine</i> , 2021, 88, 144-146.	2.2	32

#	ARTICLE	IF	CITATIONS
91	Cutaneous vasculitis following COVID-19 vaccination. <i>Lancet Rheumatology</i> , The, 2021, 3, e743-e744.	3.9	32
92	Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 440-441.	0.9	32
93	Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. <i>Arthritis Research and Therapy</i> , 2019, 21, 54.	3.5	31
94	Intrathecal rituximab for IgG ₄ -related hypertrophic pachymeningitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 441-444.	1.9	30
95	Therapeutic strategies for virus-negative myocarditis: a comprehensive review. <i>European Journal of Internal Medicine</i> , 2020, 77, 9-17.	2.2	30
96	Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 816-817.	0.9	30
97	Continuous positive airway pressure and pronation outside the Intensive Care Unit in COVID-19 acute respiratory distress syndrome. <i>Minerva Medica</i> , 2022, 113, .	0.9	30
98	Tocilizumab in patients with multisystem Erdheim-Chester disease. <i>Oncolmmunology</i> , 2017, 6, e1318237.	4.6	29
99	Diamine Oxidase Supplementation in Chronic Spontaneous Urticaria: A Randomized, Double-Blind Placebo-Controlled Study. <i>International Archives of Allergy and Immunology</i> , 2018, 176, 268-271.	2.1	29
100	Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review.. <i>European Journal of Internal Medicine</i> , 2020, 78, 17-25.	2.2	29
101	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. <i>Frontiers in Pharmacology</i> , 2020, 11, 598308.	3.5	29
102	Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation. <i>Inflammation Research</i> , 2022, 71, 293-307.	4.0	29
103	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 187-195.	0.8	29
104	Non-specific gastrointestinal features: Could it be Fabry disease?. <i>Digestive and Liver Disease</i> , 2018, 50, 429-437.	0.9	28
105	The conundrum of interleukin-6 blockade in COVID-19. <i>Lancet Rheumatology</i> , The, 2020, 2, e579-e580.	3.9	28
106	A Relapsing Inflammatory Syndrome and Active Human Herpesvirus 8 Infection. <i>New England Journal of Medicine</i> , 2005, 353, 156-163.	27.0	27
107	Budd-Chiari Syndrome in a Patient With Ulcerative Colitis. <i>Journal of Clinical Gastroenterology</i> , 2000, 30, 203-204.	2.2	27
108	Eosinophilic Granulomatosis With Polyangiitis. <i>Chest</i> , 2020, 157, 1086-1099.	0.8	26

#	ARTICLE	IF	CITATIONS
109	Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors. <i>Journal of Autoimmunity</i> , 2020, 108, 102397.	6.5	26
110	Efficacy and safety of TNF- $\hat{\pm}$ antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. <i>Rheumatology</i> , 2022, 61, 1376-1384.	1.9	26
111	Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. <i>Frontiers in Immunology</i> , 2021, 12, 653950.	4.8	26
112	Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. <i>Journal of Autoimmunity</i> , 2021, 116, 102545.	6.5	25
113	COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. <i>Lancet Rheumatology</i> , The, 2021, 3, e166-e168.	3.9	25
114	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF- $\hat{\pm}$ Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. <i>Mediators of Inflammation</i> , 2020, 2020, 1-12.	3.0	24
115	Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 509-514.	3.4	24
116	Assessment of Tocilizumab in the Treatment of Cancer Cachexia. <i>Journal of Clinical Oncology</i> , 2013, 31, 2970-2970.	1.6	23
117	Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience. <i>Rheumatology</i> , 2020, 59, 171-175.	1.9	23
118	Engagement of CD30 shapes the secretion of cytokines by human $\hat{\pm}$ T cells. <i>European Journal of Immunology</i> , 2000, 30, 2172-2180.	2.9	22
119	Common diagnoses in Internal Medicine in Europe 2009: A pan-European, Multi-Centre Survey. <i>European Journal of Internal Medicine</i> , 2010, 21, 449-452.	2.2	22
120	Diffusion-Weighted Magnetic Resonance Imaging Detects Vessel Wall Inflammation in Patients With Giant Cell Arteritis. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1879-1882.	5.3	22
121	Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 482-490.	1.1	22
122	High blood levels of chromogranin A in giant cell arteritis identify patients refractory to corticosteroid treatment. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 293-295.	0.9	21
123	Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. <i>Rheumatology</i> , 2020, 59, 3731-3736.	1.9	21
124	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020, 7, 42.	2.6	21
125	Serum IgG4 level predicts COVID-19 related mortality. <i>European Journal of Internal Medicine</i> , 2021, 93, 107-109.	2.2	21
126	Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series. <i>Arthritis and Rheumatology</i> , 2022, 74, 1302-1303.	5.6	21

#	ARTICLE	IF	CITATIONS
127	Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts. <i>Arthritis Research and Therapy</i> , 2019, 21, 275.	3.5	20
128	Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: A prospective cohort study. <i>Journal of Autoimmunity</i> , 2020, 106, 102330.	6.5	20
129	Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis. <i>Pancreatology</i> , 2021, 21, 1395-1401.	1.1	20
130	Hypoglycaemia and Lactic Acidosis in a MALT Non Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2002, 43, 1341-1342.	1.3	19
131	Skewing of cytotoxic activity and chemokine production, but not of chemokine receptor expression, in human type-1/-2 Th1 lymphocytes. <i>European Journal of Immunology</i> , 2002, 32, 2934-2943.	2.9	19
132	Prevalence of Takayasu arteritis in young women with acute ischemic heart disease. <i>International Journal of Cardiology</i> , 2018, 252, 21-23.	1.7	19
133	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). <i>European Respiratory Journal</i> , 2021, 57, 2004158.	6.7	19
134	A radiological predictor for pneumomediastinum/pneumothorax in COVID-19 ARDS patients. <i>Journal of Critical Care</i> , 2021, 66, 14-19.	2.2	19
135	QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk. <i>International Journal of Cardiology</i> , 2017, 239, 33.	1.7	18
136	Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro. <i>Frontiers in Microbiology</i> , 2020, 11, 1704.	3.5	18
137	Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study. <i>European Journal of Internal Medicine</i> , 2021, 84, 63-67.	2.2	18
138	Correspondence on Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e159-e159.	0.9	18
139	Engagement of CD30 shapes the secretion of cytokines by human Th1 T cells. <i>European Journal of Immunology</i> , 2000, 30, 2172.	2.9	18
140	Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease. <i>Journal of Neurology</i> , 2018, 265, 273-284.	3.6	17
141	The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. <i>Oncotarget</i> , 2018, 7, e1440929.	4.6	17
142	Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis. <i>Nature Communications</i> , 2021, 12, 4559.	12.8	17
143	TNF- α in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. <i>Rheumatology</i> , 2014, 53, 198-200.	1.9	16
144	The Spectrum of COVID-19-Associated Myocarditis: A Patient-Tailored Multidisciplinary Approach. <i>Journal of Clinical Medicine</i> , 2021, 10, 1974.	2.4	16

#	ARTICLE	IF	CITATIONS
145	Clinical Applications of FDG-PET Scan in Arrhythmic Myocarditis. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1771-1780.	5.3	16
146	Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1752-1761.	1.9	15
147	Current treatment options and safety considerations when treating adult-onset Still's disease. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1549-1558.	2.4	15
148	Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. <i>Rheumatology</i> , 2021, 60, 728-736.	1.9	15
149	Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e11-e11.	0.9	15
150	Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease. <i>Oncolmmunology</i> , 2016, 5, e1181244.	4.6	14
151	Drug retention rates of biological agents in adult onset Still's disease. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1-6.	3.4	14
152	Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year. <i>Clinical Immunology</i> , 2021, 231, 108845.	3.2	14
153	Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials. <i>Annals of Intensive Care</i> , 2021, 11, 152.	4.6	14
154	Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e143-e146.	0.9	13
155	Methotrexate as Induction of Remission Therapy for Type 1 Autoimmune Pancreatitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 831-833.	0.4	13
156	IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e829-e831.	3.9	13
157	Basal Serum Diamine Oxidase Levels as a Biomarker of Histamine Intolerance: A Retrospective Cohort Study. <i>Nutrients</i> , 2022, 14, 1513.	4.1	13
158	Systemic lupus erythematosus and COVID-19: what we know so far. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-218601.	0.9	12
159	Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. <i>Current Pharmaceutical Design</i> , 2021, 27, 4245-4252.	1.9	12
160	Novel Coronavirus Disease (COVID-19) in Italian Patients: Gender Differences in Presentation and Severity. <i>Saudi Journal of Medicine and Medical Sciences</i> , 2021, 9, 59.	0.8	12
161	Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology. <i>Journal of Rheumatology</i> , 2022, 49, 176-185.	2.0	12
162	Juxta-vertebral lesions in granulomatosis with polyangiitis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 356-360.	3.4	11

#	ARTICLE	IF	CITATIONS
163	Lung ultrasound B-lines in systemic sclerosis: cut-off values and methodological indications for interstitial lung disease screening. <i>Rheumatology</i> , 2022, 61, SI56-SI64.	1.9	11
164	Diagnosing Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, e19-e19.	0.9	10
165	Response to: "More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia" by Ferraccioli. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e158-e158.	0.9	10
166	Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. <i>Blood</i> , 2021, 138, 1554-1569.	1.4	10
167	A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM). <i>Frontiers in Medicine</i> , 2021, 8, 723506.	2.6	10
168	Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation. <i>Rheumatology</i> , 2022, 61, 4409-4419.	1.9	10
169	The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study. <i>Vaccines</i> , 2022, 10, 663.	4.4	10
170	The impact of fever/hyperthermia in the diagnosis of Fabry: A retrospective analysis. <i>European Journal of Internal Medicine</i> , 2016, 32, 26-30.	2.2	9
171	Large-vessel Vasculitis Affecting the Aorta and its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature. <i>Journal of Rheumatology</i> , 2020, 47, 1780-1784.	2.0	9
172	Erdheim-Chester disease: An in vivo human model of M ϕ activation at the crossroad between chronic inflammation and cancer. <i>Journal of Leukocyte Biology</i> , 2020, 108, 591-599.	3.3	9
173	Drug reaction with eosinophilia and systemic symptoms (DRESS) in patients with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1190-1192.	6.0	9
174	IgG4-related disease and allergen-specific immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 631-633.	1.0	9
175	Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. <i>Autoimmunity Reviews</i> , 2021, 20, 102981.	5.8	9
176	Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 129-134.	0.8	9
177	Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1769-1772.	0.9	9
178	Erdheim-Chester Disease. <i>Clinical Nuclear Medicine</i> , 2011, 36, 704-706.	1.3	8
179	Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera. <i>Medicine (United States)</i> , 2016, 95, e3697.	1.0	8
180	The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. <i>Joint Bone Spine</i> , 2019, 86, 363-368.	1.6	8

#	ARTICLE	IF	CITATIONS
181	3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 862-864.	0.9	8
182	Response to: "Correspondence on "Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey" by Comarmond et al". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e31-e31.	0.9	8
183	Granulocyte-macrophage colony stimulating factor in COVID-19: friend or foe?. <i>Lancet Rheumatology</i> , The, 2021, 3, e394-e395.	3.9	8
184	Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine. <i>Vaccine</i> , 2021, 39, 6464-6469.	3.8	8
185	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 187-195.	0.8	8
186	Rheumatoid Arthritis, Systemic Lupus Erythematosus, and STAT4. <i>New England Journal of Medicine</i> , 2007, 357, 2517-2518.	27.0	7
187	Attitudes towards and practice of venous thromboembolism prevention in general internal medicine wards. <i>Thrombosis Research</i> , 2012, 129, 573-576.	1.7	7
188	Serum CXCL12 levels on hospital admission predict mortality in patients with severe sepsis/septic shock. <i>American Journal of Emergency Medicine</i> , 2015, 33, 1802-1804.	1.6	7
189	Pancreatic involvement in Legionella pneumonia. <i>Infection</i> , 2015, 43, 367-370.	4.7	7
190	Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin. <i>Internal and Emergency Medicine</i> , 2017, 12, 1059-1067.	2.0	7
191	Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance. <i>Journal of Clinical Rheumatology</i> , 2019, Publish Ahead of Print, .	0.9	7
192	Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. <i>Mediators of Inflammation</i> , 2020, 2020, 1-6.	3.0	7
193	Persistence of circulating T-follicular helper cells after rituximab is associated with relapse of IgG4-related disease. <i>Rheumatology</i> , 2021, 60, 3947-3949.	1.9	7
194	One year later: The case of tocilizumab in COVID-19. <i>European Journal of Internal Medicine</i> , 2022, 95, 5-6.	2.2	7
195	Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates. <i>Diagnostics</i> , 2021, 11, 2165.	2.6	7
196	Effectiveness and safety of infliximab dose escalation in patients with refractory Takayasu arteritis: A real-life experience from a monocentric cohort. <i>Modern Rheumatology</i> , 2022, 32, 406-412.	1.8	7
197	Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases. <i>Clinical Rheumatology</i> , 2022, 41, 2261-2267.	2.2	7
198	Anticoagulation as secondary prevention of massive lung thromboses in hospitalized patients with COVID-19. <i>European Journal of Internal Medicine</i> , 2022, 100, 21-24.	2.2	7

#	ARTICLE	IF	CITATIONS
199	Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMILE) Cohort. <i>Journal of Clinical Medicine</i> , 2022, 11, 3587.	2.4	7
200	BRAF Mutations in Erdheim-Chester Disease. <i>Dermatologic Clinics</i> , 2016, 34, xi-xii.	1.7	6
201	Successful use of sirolimus in a patient with cardiac microangiopathy in primary antiphospholipid syndrome. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 509-510.	1.1	6
202	Colchicine as a new therapeutic option for antithyroid arthritis syndrome. <i>Rheumatology</i> , 2020, 59, 1452-1453.	1.9	6
203	Colchicine treatment in community healthcare setting to prevent severe COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e198-e198.	0.9	6
204	<p>Multimodal Chorioretinal Imaging in Erdheim-Chester Disease</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 581-588.	1.8	6
205	Urgent manifestations of immunoglobulin G₄-related disease. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 48-51.	1.1	6
206	Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease Italian study group. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1498-1501.	0.9	6
207	Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and Alexithymia. <i>Current Rheumatology Reports</i> , 2021, 23, 52.	4.7	6
208	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndromeâ€™ Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. <i>Frontiers in Medicine</i> , 2021, 8, 668173.	2.6	6
209	Utility of the â€™2019 ACR/EULAR classification criteriaâ€™ for the management of patients with IgG4-related disease. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 761-765.	3.4	6
210	Long-term clinical outcomes of patients with rheumatoid arthritis and concomitant coronary artery disease. <i>American Journal of Cardiovascular Disease</i> , 2017, 7, 9-18.	0.5	6
211	The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis. <i>Journal of Multidisciplinary Healthcare</i> , 2022, Volume 15, 815-824.	2.7	6
212	Methotrexate in refractory bilateral juvenile temporal arteritis: Report of a case. <i>Modern Rheumatology</i> , 2016, 26, 276-277.	1.8	5
213	Advances in potential targeted therapies for Erdheim-Chester disease. <i>Expert Opinion on Orphan Drugs</i> , 0, 1-8.	0.8	5
214	IgG4-Related Disease of the Oral Cavity. Case Series from a Large Single-Center Cohort of Italian Patients. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8179.	2.6	5
215	Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: â€™Correspondence on: â€™Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammationâ€™ an open-label cohort studyâ€™ by Della-Torre & al & by Cheng and Zhang. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e197-e197.	0.9	5
216	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab015.	0.7	5

#	ARTICLE	IF	CITATIONS
217	The target on B cells in Systemic Sclerosis: a "midsummer dream" to extinguish inflammation and prevent early disease progression to fibrosis. <i>Clinical Rheumatology</i> , 2021, 40, 2529-2533.	2.2	5
218	Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients. <i>Minerva Anestesiologica</i> , 2021, 87, 891-902.	1.0	5
219	Virus-encoded chemokines, chemokine receptors and chemokine-binding proteins: new paradigms for future therapy. <i>Future Virology</i> , 2007, 2, 353-368.	1.8	4
220	The European Diploma of Internal Medicine " Perspectives on the exam from across Europe. <i>European Journal of Internal Medicine</i> , 2010, 21, 46-47.	2.2	4
221	A Bitter Effect: Thrombocytopenia Induced by a Quinidine-containing Beverage. <i>American Journal of Medicine</i> , 2014, 127, e1-e2.	1.5	4
222	Effect of anakinra in COVID-19 " Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e524-e525.	3.9	4
223	Mavrilimumab for severe COVID-19 " Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e662-e663.	3.9	4
224	Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database. <i>Rheumatology</i> , 2021, 61, 213-222.	1.9	4
225	The course of action for effective anti-cytokine treatment in COVID-19. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 1353-1354.	10.7	4
226	Clinical features and outcomes of COVID-19 in patients with IgG4-related disease: a European multi-centre study. <i>Rheumatology</i> , 2022, 61, e109-e111.	1.9	4
227	Chronic Ulcer by Cutaneous GvHD After Bone Marrow Transplantation Treated With Skin Allograft From HLA-Identical Donor. <i>International Journal of Lower Extremity Wounds</i> , 2016, 15, 139-141.	1.1	3
228	Spontaneous Coronary-Artery Dissection. <i>New England Journal of Medicine</i> , 2021, 384, 1077-1078.	27.0	3
229	An Italian Disease-Based Registry of Axial and Peripheral Spondyloarthritis: The SIRENA Study. <i>Frontiers in Medicine</i> , 2021, 8, 711875.	2.6	3
230	Serum IgG4 elevation in hyper-inflamed COVID-19 patients. Author's reply. <i>European Journal of Internal Medicine</i> , 2021, , .	2.2	3
231	Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 179-188.	1.7	3
232	Retention rate of IL-1 inhibitors in Schnitzler's syndrome. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	3
233	A Relapsing Inflammatory Syndrome and HHV-8. <i>New England Journal of Medicine</i> , 2005, 353, 1746-1747.	27.0	2
234	Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2018, 25, 1.	0.9	2

#	ARTICLE	IF	CITATIONS
235	SAT0490â€¦IL-1 BLOCKADE IN PEDIATRIC RECURRENT PERICARDITIS: A MULTICENTRIC RETROSPECTIVE STUDY ON THE ITALIAN COHORT. , 2019, , .		2
236	Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis. Journal of the Neurological Sciences, 2020, 418, 117104.	0.6	2
237	A Novel Histiocytosis With Synovial and Skin Involvement. Annals of Internal Medicine, 2021, 174, 273-274.	3.9	2
238	Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis. Clinical Immunology Communications, 2022, 2, 23-29.	1.2	2
239	Gas-exchange deficit and systemic hypoperfusion in COVID-19 and non-COVID-19 young adult patients with pneumonia. Panminerva Medica, 2024, 66, .	0.8	2
240	Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of <i>KRAS</i>-mutated histiocytosis. Rheumatology, 2022, 61, e93-e96.	1.9	2
241	Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study. Rheumatology, 2022, 62, 341-346.	1.9	2
242	Biological Features of HHV-6. Perspectives in Medical Virology, 2006, 12, 59-75.	0.1	1
243	Introducing the â€œInternal Medicine Flashcardsâ€œ: Call for papers. European Journal of Internal Medicine, 2013, 24, 483.	2.2	1
244	Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy. Journal of Rheumatology, 2019, 46, 1421-1422.	2.0	1
245	How to obtain severe hypoglycemia without causing brain or cardiac damage. Medical Hypotheses, 2019, 130, 109276.	1.5	1
246	FRI0278â€¦OFF-LABEL USE OF BIOLOGICAL THERAPIES IN RELAPSING AND/OR REFRACTORY EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS). , 2019, , .		1
247	AB0446â€¦REAL-LIFE USE OF BARICITINIB IN RHEUMATOID ARTHRITIS: A MULTICENTER OBSERVATIONAL STUDY OF 150 PATIENTS. , 2019, , .		1
248	Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness. European Journal of Internal Medicine, 2020, 82, 23-24.	2.2	1
249	Clinically isolated aortitis successfully treated with methotrexate monotherapy. Rheumatology, 2020, 59, e54-e56.	1.9	1
250	Canakinumab injection for the treatment of active Stillâ€™s disease, including adult-onset Stillâ€™s disease. Expert Opinion on Orphan Drugs, 2021, 9, 77-86.	0.8	1
251	Clinical and dermoscopic description of accelerated nodulosis after tocilizumab treatment for an isolated aortitis with coronary involvement. International Journal of Dermatology, 2021, 60, e359-e361.	1.0	1
252	Cardiac immuneâ€¦related adverse events: anâ€¦immuneâ€¦cardioâ€¦oncology puzzle. European Journal of Heart Failure, 2021, 23, 1748-1749.	7.1	1

#	ARTICLE	IF	CITATIONS
253	In the limelight: AA amyloidosis exposes TNF receptor-1 associated periodic syndrome. <i>Rheumatology</i> , 2021, 60, 5493-5494.	1.9	1
254	Subacute cutaneous lupus erythematosus induced by dupilumab: a novel possible association with specific pathogenetic mechanisms. <i>Italian Journal of Dermatology and Venereology</i> , 2021, , .	0.2	1
255	Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 129-134.	0.8	1
256	Fibromyalgia severity according to age categories: results of a cross-sectional study from a large national database. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	1
257	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	1
258	Lights and shadows on JAK inhibitors for Ankylosing Spondylitis. <i>European Journal of Internal Medicine</i> , 2022, 102, 43-44.	2.2	1
259	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 695-695.	0.8	1
260	Corrigendum to "Common diagnoses in internal medicine in Europe 2009: A pan-European, multi-centre survey" [Eur J Intern Med 21 (5) (2010) 449-452]. <i>European Journal of Internal Medicine</i> , 2012, 23, e177.	2.2	0
261	Proposal of a rating scale to recognize Fabry disease in patients with nonspecific gastrointestinal symptoms. <i>Molecular Genetics and Metabolism</i> , 2018, 123, S63-S64.	1.1	0
262	357. "EFFICACY AND SAFETY OF TOCILIZUMAB IN GIANT CELL ARTERITIS: A MONOCENTRIC REAL-LIFE EXPERIENCE. <i>Rheumatology</i> , 2019, 58, .	1.9	0
263	168. "GENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASU'S ARTERITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
264	233. "ALVEOLAR HEMORRHAGE IN ANCA-ASSOCIATED VASCULITIS: LONG TERM OUTCOME AND MORTALITY PREDICTORS. A RETROSPECTIVE LONG-TERM STUDY ON 106 ITALIAN PATIENTS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
265	273. "TAKAYASU'S ARTERITIS: BEYOND THE VESSELS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
266	288. "DRUG RETENTION AND DISCONTINUATION REASONS BETWEEN EIGHT BIOLOGICS IN PATIENTS WITH TAKAYASU'S ARTERITIS: A SINGLE-CENTER EXPERIENCE. <i>Rheumatology</i> , 2019, 58, .	1.9	0
267	337. "MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGITIS: A SINGLE CENTRE REAL-LIFE EXPERIENCE. <i>Rheumatology</i> , 2019, 58, .	1.9	0
268	FRI0585 "EFFICACY OF CANAKINUMAB AS FIRST-LINE BIOLOGIC AGENT IN ADULT-ONSET STILL'S DISEASE. , 2019, , .		0
269	AB0613 "PRESENTATION OF TAKAYASU ARTERITIS ACCORDING TO THE AGE OF ONSET IN A MONOCENTRIC ITALIAN COHORT. , 2019, , .		0
270	AB0620 "EFFICACY AND SAFETY OF TOCILIZUMAB IN GIANT CELL ARTERITIS: A MONOCENTRIC REAL-LIFE EXPERIENCE. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
271	THU0570â€¦EFFICACY AND SAFETY OF ANAKINRA IN THE TREATMENT OF AUTOIMMUNE MYOCARDITIS. , 2019, , .		0
272	THU0293â€¦DRUG RETENTION AND DISCONTINUATION REASONS BETWEEN SEVEN BIOLOGICS IN PATIENTS WITH TAKAYASUâ€™S ARTERITIS: A SINGLE-CENTER EXPERIENCE. , 2019, , .		0
273	SAT0217â€¦EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: CLINICAL PREDICTORS OF LONG-TERM ASTHMA SEVERITY. , 2019, , .		0
274	SAT0221â€¦OFF-LABEL USE OF BIOLOGICAL THERAPIES IN RELAPSING AND/OR REFRACTORY POLYARTERITIS NODOSA. , 2019, , .		0
275	THU0319â€¦TAKAYASUâ€™S ARTERITIS: BEYOND THE VESSELS. , 2019, , .		0
276	Le Relapsing Polychondritis Damage Index (RPDAM): dÃ©veloppement dâ€™un score lâ€™sionnel au cours de la polychondrite atrophiante. Revue Du Rhumatisme (Edition Francaise), 2020, 87, 122-127.	0.0	0
277	Anakinra in COVIDâ€“19â€™How to Interpret Elevations of Serum Liver Enzymes: Comment on the Article by Navarroâ€™MillÃ¡n et al. Arthritis and Rheumatology, 2021, 73, 549-549.	5.6	0
278	Efficacy and Safety of IL-6 Inhibitors in Patients with COVID-19 Pneumonia: A Systematic Review and Meta-Analysis of Multicentre, Randomised Trials. SSRN Electronic Journal, 0, , .	0.4	0
279	The choice of early treatment and the impact of future relapses in adult onset Stillâ€™s disease. Rheumatology, 2021, 60, 2500-2501.	1.9	0
280	Catastrophic antiphospholipid syndrome presenting with aortic barrage: case report and review of the literature. Lupus, 2021, 30, 1005-1009.	1.6	0
281	Angiotensin II infusion and markers of organ function in invasively ventilated COVID-19 patients. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2021, 23, 215-224.	0.1	0
282	Myocardial infarction in giant cell arteritis: It is all a matter of balance.. European Journal of Internal Medicine, 2021, 89, 1-2.	2.2	0
283	Response to â€™Correspondence on â€™Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric surveyâ€™â€™ by Montero et al. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2021-220959.	0.9	0
284	Rapid response to cyclosporine in a rare case of pityriasis rubra pilaris with autoantibodies and systemic symptoms. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 728-730.	0.8	0
285	505. Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study. Open Forum Infectious Diseases, 2021, 8, S354-S355.	0.9	0
286	Improvements of vascular outcomes in systemic sclerosis: halfway through, but still far to go. Rheumatology, 2022, , .	1.9	0
287	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. Clinical and Experimental Rheumatology, 2021, 39, 695.	0.8	0
288	Retention rate of IL-1 inhibitors in Schnitzler's syndrome.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0

#	ARTICLE	IF	CITATIONS
289	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0
290	Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzle. European Journal of Internal Medicine, 2022, , .	2.2	0